Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Authors
Keywords
Benefits, Cardiovascular, Fractures, Ketoacidosis, Renal, Review, Risks, SGLT2 inhibitors, Type 2 diabetes
Journal
DIABETOLOGIA
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-07-21
DOI
10.1007/s00125-018-4663-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
- (2017) Michael Fralick et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
- (2017) Bernard Zinman et al. STROKE
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
- (2017) Kenneth W. Mahaffey et al. CIRCULATION
- Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists
- (2016) David Z.I. Cherney et al. CIRCULATION
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials
- (2016) H. L. Tang et al. DIABETES OBESITY & METABOLISM
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- (2016) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney
- (2016) Biff F. Palmer et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2015) Silvio E. Inzucchi et al. DIABETOLOGIA
- SGLT2 Inhibitors May Predispose to Ketoacidosis
- (2015) Simeon I. Taylor et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
- (2015) Lana Pinto et al. Diabetology & Metabolic Syndrome
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- (2014) Martin Ridderstråle et al. Lancet Diabetes & Endocrinology
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
- (2013) Harold E. Bays et al. Obesity
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
- (2012) J. Rosenstock et al. DIABETES CARE
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
- (2012) K. Stenlöf et al. DIABETES OBESITY & METABOLISM
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started